Drugs / rVA576
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT04037891 | Mar 2019 → Apr 2020 | atopic conjunctivitis, atopic keratoconjunctivitis, vernal keratoconjunctivitis | AKARI Therapeutics | Terminated | Met primary |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT04035733 | Sep 2018 → Mar 2020 | bullous pemphigoid | AKARI Therapeutics | Completed | Met primary |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT03588026 | Jun 2018 → Sep 2020 | paroxysmal nocturnal hemoglobinuria | AKARI Therapeutics | Completed | Met primary |
| Phase 3 | NCT03829449 | Mar 2017 → Aug 2020 | paroxysmal nocturnal hemoglobinuria | AKARI Therapeutics | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 19 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rVA576 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03588026 ↗ |
| Known as | Coversin | “The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin).” NCT03829449 ↗ |
| Action | Inhibit | “prevents the cleavage of C5 by C5 convertase” NCT03588026 ↗ |
| Modality | Protein / enzyme biologic | “a small protein complement C5 inhibitor” NCT03588026 ↗ |
| Route | Subcutaneous | “daily subcutaneous injection” NCT03588026 ↗ |
| Target | C5 | “complement C5 inhibitor” NCT03588026 ↗ |